A new series of N-aryl-N'-3,4-dihydro-2,2-dimethyl-2H-1-
benzopyran-4-yl)ureas bearing an alkoxycarbonylamino group at the 6-position were synthesized and examined as putative
anticancer agents targeting
sirtuins in
glioma cells. On the basis of computational docking combined to in vitro
sirtuin 1/2 inhibition assays, we selected
compound 18 [R/S-N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-
benzopyran-4-yl)
urea] which displays a potent antiproliferative activity on various
glioma cell types, assessed by quantitative videomicroscopy, eventually triggering senescence. The impact on normal glial cells was lower with a selectivity index of >10. Furthermore, human U373 and Hs683
glioblastoma cell lines served to demonstrate the inhibitory activity of 18 against
histone deacetylase (HDAC) class III
sirtuins 1 and 2 (
SIRT1/2) by quantifying acetylation levels of
histone and non-
histone proteins. The translational potential of 18 was validated by an NCI-60 cell line screen and validation of growth inhibition of drug resistant
cancer cell models. Eventually, the anticancer potential of 18 was validated in 3D
glioblastoma spheroids and in vivo by zebrafish xenografts. In summary,
compound 18 is the first representative of a new class of
SIRT inhibitors opening new perspectives in the medicinal chemistry of
HDAC inhibitors.